4.3 Pulmonary Disorders
Key Takeaways
- Asthma management is stepwise: inhaled corticosteroid (ICS)-containing therapy is the controller foundation, and short-acting beta-agonist (SABA) reliever-only treatment without an inhaled corticosteroid is no longer preferred for most patients.
- Chronic obstructive pulmonary disease (COPD) maintenance therapy is built on long-acting bronchodilators (LABA and/or long-acting muscarinic antagonist, LAMA), with inhaled corticosteroids added in selected patients such as those with frequent exacerbations or eosinophilia.
- Inhaler technique and device selection are tested directly; metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft-mist inhalers each require different inhalation maneuvers, and DPIs require a forceful inhalation.
- Asthma and COPD exacerbations are commonly managed with systemic corticosteroids and intensified bronchodilation; COPD exacerbations with increased sputum purulence often warrant antibiotics.
- Smoking cessation pharmacotherapy includes nicotine replacement therapy, varenicline, and bupropion, paired with behavioral support to maximize quit rates.
Pulmonary Therapeutics and Patient-Centered Care
Respiratory disease is high-yield on the NAPLEX because correct therapy depends on disease type, control or exacerbation status, and the patient's ability to use a device correctly. Selecting the right drug is only half the answer; the exam frequently tests whether you can also choose and teach the right inhaler.
Asthma
Asthma is a chronic inflammatory airway disorder causing reversible bronchoconstriction, wheeze, cough, and dyspnea. Two therapeutic roles must be distinguished: controller therapy that reduces airway inflammation and prevents exacerbations, and reliever therapy for acute symptoms.
Stepwise Principles
Modern asthma care is stepwise: therapy is stepped up if control is inadequate and stepped down once control is sustained. The central change in current guideline thinking is that inhaled corticosteroid (ICS)-containing therapy is the foundation of treatment. Using a short-acting beta-agonist (SABA) alone, with no inhaled corticosteroid, is no longer preferred for most patients because it does not treat the underlying inflammation that drives exacerbations.
| Drug class | Examples | Role | Monitoring / counseling |
|---|---|---|---|
| Inhaled corticosteroids (ICS) | budesonide, fluticasone, beclomethasone | Controller foundation | Rinse mouth after use to reduce oral candidiasis; assess control and technique |
| Long-acting beta-agonists (LABA) | formoterol, salmeterol | Add-on controller (always with an ICS in asthma) | Never use a LABA without an ICS in asthma |
| Long-acting muscarinic antagonist (LAMA) | tiotropium | Add-on for inadequate control | Counsel on device technique; dry mouth |
| Leukotriene receptor antagonist | montelukast | Alternative/add-on controller | Counsel on neuropsychiatric warnings |
| Short-acting beta-agonist (SABA) | albuterol | Reliever for acute symptoms | Frequent use signals poor control |
| Biologics | targeted monoclonal antibodies | Severe, specific phenotypes | Specialist-directed; phenotype-guided |
Counseling pearl: Frequent SABA use, nighttime symptoms, or rescue inhaler refills more than expected indicate poor control and should trigger a step-up review of adherence and inhaler technique before escalating drug therapy.
Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive disorder of persistent airflow limitation, usually from long-term noxious exposure such as tobacco smoke. Unlike asthma, the maintenance backbone is long-acting bronchodilation, not inhaled corticosteroids.
Maintenance Strategy
- LAMA and/or LABA long-acting bronchodilators are the maintenance foundation, used alone or in dual combination based on symptom burden and exacerbation history.
- Inhaled corticosteroids are added in selected patients, such as those with frequent exacerbations or higher blood eosinophils, balanced against an increased pneumonia risk.
- SABA or short-acting muscarinic antagonist provides as-needed symptom relief.
- Non-pharmacologic care including smoking cessation, vaccination, and pulmonary rehabilitation is essential and frequently the best answer in a person-centered question.
Inhaler Technique and Device Selection
Device errors are a leading cause of "treatment failure" that is actually a technique problem. The NAPLEX tests recognition of the correct maneuver for each device class.
| Device | Inhalation maneuver | Key counseling point |
|---|---|---|
| Metered-dose inhaler (MDI) | Slow, deep inhalation with actuation coordination | A spacer/valved holding chamber improves delivery and reduces coordination errors |
| Dry powder inhaler (DPI) | Quick, forceful, deep inhalation | Do not exhale into the device; humidity can clump powder |
| Soft-mist inhaler | Slow, steady inhalation | Requires priming/preparation per device instructions |
| Nebulizer | Normal tidal breathing through mouthpiece/mask | Useful when a patient cannot coordinate handheld devices |
High-yield contrast: An MDI requires a slow, deep breath, whereas a DPI requires a quick, forceful breath because the patient's own inspiratory effort disaggregates the powder. Choosing a device the patient can physically use correctly is a person-centered decision the exam rewards.
Exacerbation Management
An exacerbation is an acute worsening of respiratory symptoms beyond normal day-to-day variation.
- Asthma exacerbation: intensified short-acting bronchodilation and a course of systemic corticosteroids for moderate-to-severe events, with oxygen as needed and reassessment of controller therapy and technique afterward.
- COPD exacerbation: intensified bronchodilation and systemic corticosteroids; antibiotics are added when there are signs of a likely bacterial cause, such as increased sputum purulence with increased volume or dyspnea. After recovery, review maintenance therapy and adherence.
Smoking Cessation
Tobacco cessation is the single most impactful intervention in COPD and a recurring person-centered counseling topic. Pharmacotherapy combined with behavioral support produces the best quit rates.
| Therapy | Examples | Key counseling |
|---|---|---|
| Nicotine replacement therapy (NRT) | patch (long-acting) plus gum or lozenge (short-acting) | Combining a long-acting patch with a short-acting form improves success |
| Varenicline | varenicline | Take with food; counsel to report mood or behavior changes |
| Bupropion | sustained-release bupropion | Avoid with seizure disorder; can be combined with NRT |
Always pair pharmacotherapy with counseling, set a quit date, and arrange follow-up; the most complete answer in a cessation case usually includes both a medication and behavioral support.
Allergic Rhinitis and Adjacent Airway Conditions
Allergic rhinitis frequently coexists with asthma and is a common counseling topic. Intranasal corticosteroids (fluticasone, mometasone, budesonide) are the most effective single class for persistent symptoms; second-generation oral antihistamines (loratadine, cetirizine, fexofenadine) are preferred over sedating first-generation agents for daytime use. Counsel patients that intranasal steroids require consistent daily use for full benefit and to aim the spray slightly away from the septum to reduce epistaxis.
Oral and intranasal decongestants (pseudoephedrine, oxymetazoline) provide short-term relief but carry cautions: pseudoephedrine can raise blood pressure and is restricted at the counter, and topical oxymetazoline causes rebound congestion (rhinitis medicamentosa) if used beyond about three days.
Vaccination and Non-Pharmacologic Care in Respiratory Disease
For both asthma and COPD, the most complete person-centered answer often pairs drug therapy with prevention. Annual influenza vaccination, age- and risk-appropriate pneumococcal vaccination, and COVID-19 and RSV vaccination per current recommendations reduce exacerbations and hospitalizations. Pulmonary rehabilitation, action plans, and trigger avoidance further lower risk.
| Intervention | Why it matters in obstructive lung disease |
|---|---|
| Smoking cessation | The single most effective step to slow COPD progression |
| Influenza vaccine (annual) | Reduces exacerbations and respiratory hospitalizations |
| Pneumococcal vaccine | Lowers invasive pneumococcal disease risk |
| Inhaler technique review | Corrects "treatment failure" that is really a device error |
| Written action plan | Helps patients self-manage early symptom changes |
Exam cue: When a stable COPD or asthma vignette asks for the best additional intervention and the patient is a smoker or unvaccinated, the highest-value answer is often cessation support or an indicated vaccine rather than escalating inhaled drug therapy.
A 29-year-old patient with persistent asthma uses an albuterol inhaler several times daily as the only treatment and reports frequent nighttime symptoms. Based on current asthma management principles, what is the BEST next step?
A pharmacist is counseling a patient who was switched from a metered-dose inhaler to a dry powder inhaler. Which instruction is correct for proper dry powder inhaler technique?
A patient with COPD presents with an acute exacerbation marked by increased dyspnea, increased sputum volume, and new sputum purulence. In addition to intensified bronchodilation and a systemic corticosteroid course, which intervention is MOST appropriate?
A patient with allergic rhinitis has used an oxymetazoline nasal spray every day for two weeks and reports worsening congestion when it wears off. What is the best explanation and recommendation?
A 68-year-old patient with stable COPD on dual long-acting bronchodilator therapy is a current smoker and has not received an influenza vaccine this season. Which additional intervention provides the greatest value?